Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Rechallenge with zongertinib after trastuzumab deruxtecan in HER2-mutant lung cancer: A case report.

Lung cancer (Amsterdam, Netherlands) - 1 Aug 2026

Koba Hayato, Tambo Yuichi, Murase Yuya, Yoh Kiyotaka, Izumi Hiroki, Nishiyama Akihiro, Sone Takashi, Shimizu Takahiro, Nomura Shunichi, Ueda Tsukasa, Arai Sachiko, Tanimoto Azusa, Nanjo Shigeki, Goto Koichi, Yano Seiji

Abstract excerpt

A 65-year-old man with advanced lung adenocarcinoma underwent comprehensive genomic profile testing using a blood sample after completion of standard therapy, which identified a HER2 mutation. The HER2- tyrosine kinase inhibitor (TKI); zongertinib achieved partial response; however, the tumor grew, prompting a repeat biopsy 22 months later. Repeat biopsy demonstrated HER2 protein expression and HER2...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acrylamides
Share to Antibodies, Monoclonal, Humanized

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Camptothecin

Share to Erb-b2 Receptor Tyrosine Kinases

Share to Imidazoles

Share to Immunoconjugates

Share to Pyrimidines

Share to Trastuzumab

Source

Identifiers

PMID: 42287786
DOI: 10.1016/j.lungcan.2026.109492

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Rechallenge with zongertinib after trastuzumab deruxtecan in HER2-mutant lung cancer: A case report.PMID 42287786Read ↗

Management of HER2 alterations in non-small cell lung cancer - The past, present, and future.Semantic proximity Read ↗

HER2 Alterations in Non-Small Cell Lung Cancer: Emerging Perspectives on the Therapeutic Landscape.Semantic proximity Read ↗

[Trastuzumab Deruxtecan for EGFR-mutant Lung Adenocarcinoma with Acquired High-level HER2 Amplification: A Case Report].Semantic proximity Read ↗

Evaluating zongertinib in the treatment of patients with HER2-mutant non-small cell lung cancer.Semantic proximity Read ↗

Evaluation of zongertinib for the treatment of metastatic non-squamous non-small cell lung cancer with HER2 TKD activating mutation.Semantic proximity Read ↗

Successful Rechallenge of Trastuzumab Deruxtecan After Drug-Induced Interstitial Lung Disease in a NSCLC With HER2 Mutation: A Case ReportSemantic proximity Read ↗

HER2 in Non-Small Cell Lung Cancer: A Review of Emerging TherapiesSemantic proximity Read ↗

HER2 Therapies in Non-Small Cell Lung Cancer (NSCLC).Semantic proximity Read ↗

Emerging treatment strategies for HER2-mutant NSCLC: Striving for selectivity, efficacy, and tolerability.Semantic proximity Read ↗

The development of Zongertinib for HER2-mutant NSCLCSemantic proximity Read ↗

Zongertinib: First Approval.Semantic proximity Read ↗

HER2-Mediated Internalization of Cytotoxic Agents in ERBB2 Amplified or Mutant Lung Cancers.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.